Information Provided By:
Fly News Breaks for May 10, 2016
HZNP
May 10, 2016 | 07:09 EDT
Brean Capital said they would be buyers of Horizon Pharma on any weakness despite acknowledging shares could remain weak for the next two quarters. The firm believes the company may not meet its guidance due to pricing headwinds and slow product sales, but said the company's valuation is at an "irrational" level. Brean Capital reiterated its Buy rating and $30 price target on Horizon Pharma shares.
News For HZNP From the Last 2 Days
There are no results for your query HZNP